Dr. Evan Yu
Claim this profileFred Hutchinson Cancer Center / Seattle Cancer Care Alliance / University of Washington
Studies Bladder Cancer
Studies Skin Cancer
5 reported clinical trials
14 drugs studied
Area of expertise
1Bladder Cancer
Stage III
HER2 positive
Stage IV
2Skin Cancer
Stage III
HER2 positive
Stage IV
Affiliated Hospitals
Clinical Trials Evan Yu is currently running
PSMA PET Scan-Directed Therapy
for Prostate Cancer
This phase II trial studies how well prostate specific membrane antigen (PSMA) or fluciclovine positron emission tomography (PET)/computed tomography (CT) site-directed therapy works for treating patients with prostate cancer. PSMA or fluciclovine PET/CT may detect prostate cancer early and may help to show whether patients benefit from site directed treatment to PET detected abnormalities.
Recruiting1 award Phase 217 criteria
Disitamab Vedotin + Pembrolizumab vs Chemotherapy
for Bladder Cancer
This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease. Participants in this study will have cancer that has spread through the body (metastatic) or spread near where it started (locally advanced). In this study, there are 2 different groups. Participants will be assigned to a group randomly. Participants in the disitamab vedotin arm will get the study drug disitamab vedotin once every two weeks and pembrolizumab once every 6 weeks. Participants in the standard of care arm will get gemcitabine once a week for 2 weeks with either cisplatin or carboplatin once every 3 weeks.
Recruiting2 awards Phase 3
More about Evan Yu
Clinical Trial Related4 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Evan Yu has experience with
- Disitamab Vedotin
- Pembrolizumab
- Abiraterone
- Abiraterone Acetate
- Prednisone
- PSMA PET Scan
Breakdown of trials Evan Yu has run
Bladder Cancer
Skin Cancer
Transitional Cell Carcinoma
Urothelial Carcinoma
Stomach Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Evan Yu specialize in?
Evan Yu focuses on Bladder Cancer and Skin Cancer. In particular, much of their work with Bladder Cancer has involved Stage III patients, or patients who are HER2 positive.
Is Evan Yu currently recruiting for clinical trials?
Yes, Evan Yu is currently recruiting for 3 clinical trials in Seattle Washington. If you're interested in participating, you should apply.
Are there any treatments that Evan Yu has studied deeply?
Yes, Evan Yu has studied treatments such as Disitamab Vedotin, Pembrolizumab, Abiraterone.
What is the best way to schedule an appointment with Evan Yu?
Apply for one of the trials that Evan Yu is conducting.
What is the office address of Evan Yu?
The office of Evan Yu is located at: Fred Hutchinson Cancer Center / Seattle Cancer Care Alliance / University of Washington, Seattle, Washington 98109 United States. This is the address for their practice at the Fred Hutchinson Cancer Center / Seattle Cancer Care Alliance / University of Washington.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.